ATAI Life Sciences
Price & Volume
Stats
See more52W Range | $1.29-$6.75 |
Market Cap | $1.3B |
Shares Short | 24M |
Financials
See moreRevenue (12 Mos) | $4M |
Revenue Growth (YoY) | 1,772.5% |
Gross Profit (12 Mos) | -$43.5M |
Diluted EPS | -$2.91 |
News
See moreYahoo Finance • 17 days ago
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts
Yahoo Finance • 21 days ago
AtaiBeckley added to major US indices, increasing reach among passive investors
Yahoo Finance • 28 days ago
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
Yahoo Finance • last month
AtaiBeckley Advances BPL-003 Into Phase 3 For Treatment-Resistant Depression
About
CEO | Dr. Srinivas G. Rao M.D., Ph.D. |
Address | 250 West 34th Street, New York, NY, United States, 10119 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 99 |
